Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol

Abstract Background Patients with irresectable stage III or metastatic melanoma presenting with poor prognostic factors are usually treated with a combination of immune checkpoint inhibitors (ICIs), consisting of ipilimumab and nivolumab. This combination therapy is associated with severe immune rel...

Cijeli opis

Bibliografski detalji

Glavni autori:	J. C. Janssen, B. van Dijk, K. de Joode, M. J. B. Aarts, F. W. P. J. van den Berkmortel, C. U. Blank, M. J. Boers-Sonderen, A. J. M. van den Eertwegh, J. W. B. de Groot, M. Jalving, M. J. A. de Jonge, A. Joosse, E. Kapiteijn, A. M. Kamphuis-Huismans, K. A. T. Naipal, D. Piersma, B. Rikhof, H. M. Westgeest, G. Vreugdenhil, E. Oomen-de Hoop, E. E. A. P. Mulder, Astrid A. M. van der Veldt
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2024-05-01
Serija:	BMC Cancer
Teme:	Melanoma Ipilimumab Nivolumab Discontinuation of treatment Immune checkpoint inhibitors Treatment duration
Online pristup:	https://doi.org/10.1186/s12885-024-12336-0
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!